The safety of anidulafungin

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.

Original languageEnglish (US)
Pages (from-to)751-758
Number of pages8
JournalExpert Opinion on Drug Safety
Issue number6
StatePublished - Nov 1 2006
Externally publishedYes


  • Anidulafungin
  • Echinocandin
  • Fungi
  • Glucan synthase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'The safety of anidulafungin'. Together they form a unique fingerprint.

Cite this